Literature DB >> 25088400

Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteria.

Ioanna Parisi1, Emmanuel Tsochatzis, Hasitha Wijewantha, Manuel Rodríguez-Perálvarez, Laura De Luca, Pinelopi Manousou, Evangelia Fatourou, Giulia Pieri, Vassilios Papastergiou, Neil Davies, Dominic Yu, TuVinh Luong, Amar Paul Dhillon, Douglas Thorburn, David Patch, James O'Beirne, Tim Meyer, Andrew K Burroughs.   

Abstract

Increased preoperative inflammation scores, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and inflammation-based index (IBI) have been related to post-transplant HCC recurrence. We evaluated the association between inflammation-based scores (NLR, PLR, IBI) and post-LT HCC recurrence as well as tumor necrosis after transarterial embolization. 150 consecutive patients who underwent transplantation for HCC within the Milan criteria between 1996 and 2010 were included; data regarding inflammatory markers, patient and tumor characteristics were analyzed. NLR, PLR, and IBI were not significantly associated with post-LT HCC recurrence or worse overall survival. Increased NLR and PLR were associated with complete tumor necrosis in the subset of patients who received preoperative transarterial embolization (P < 0.05). Cox regression analysis revealed that absence of neoadjuvant transarterial therapy (OR = 4.33, 95% CI = 1.28-14.64; P = 0.02) and no fulfillment of the Milan criteria in the explanted liver (OR = 3.34, 95% CI = 1.08-10.35; P = 0.04) were independently associated with post-LT HCC recurrence inflammation-based scores did not predict HCC recurrence post-LT in our group of patients. NLR and PLR were associated with better response to TAE, as this was recorded histologically in the explanted liver. Histological fulfillment of the Milan criteria and absence of neoadjuvant transarterial treatment were significantly associated with post-LT HCC recurrence.
© 2014 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25088400     DOI: 10.1002/lt.23969

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  17 in total

Review 1.  Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation.

Authors:  Marta Guerrero-Misas; Manuel Rodríguez-Perálvarez; Manuel De la Mata
Journal:  World J Hepatol       Date:  2015-04-08

2.  The platelet-to-lymphocyte ratio predicts poor survival in patients with huge hepatocellular carcinoma that received transarterial chemoembolization.

Authors:  Tong-Chun Xue; Qing-An Jia; Ning-Ling Ge; Bo-Heng Zhang; Yan-Hong Wang; Zheng-Gang Ren; Sheng-Long Ye
Journal:  Tumour Biol       Date:  2015-03-04

3.  Prognostic value of preoperative peripheral monocyte count in patients with hepatocellular carcinoma after liver transplantation.

Authors:  Qing-Qi Ren; Shun-Jun Fu; Qiang Zhao; Zhi-Yong Guo; Fei Ji; Mao-Gen Chen; Lin-Wei Wu; Xiao-Shun He
Journal:  Tumour Biol       Date:  2016-01-12

Review 4.  Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.

Authors:  Umberto Cillo; Tommaso Giuliani; Marina Polacco; Luz Maria Herrero Manley; Gino Crivellari; Alessandro Vitale
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 5.  Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun.

Authors:  Taizo Hibi; Osamu Itano; Masahiro Shinoda; Yuko Kitagawa
Journal:  Surg Today       Date:  2016-04-29       Impact factor: 2.549

6.  Expansion of the Milan criteria without any sacrifice: combination of the Hangzhou criteria with the pre-transplant platelet-to-lymphocyte ratio.

Authors:  Weiliang Xia; Qinghong Ke; Hua Guo; Weilin Wang; Min Zhang; Yan Shen; Jian Wu; Xiao Xu; Sheng Yan; Jun Yu; Mangli Zhang; Shusen Zheng
Journal:  BMC Cancer       Date:  2017-01-05       Impact factor: 4.430

Review 7.  Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.

Authors:  Xingshun Qi; Jianjun Li; Han Deng; Hongyu Li; Chunping Su; Xiaozhong Guo
Journal:  Oncotarget       Date:  2016-07-19

Review 8.  Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma.

Authors:  Marc Najjar; Surbhi Agrawal; Jean C Emond; Karim J Halazun
Journal:  J Hepatocell Carcinoma       Date:  2018-01-18

Review 9.  Prognostic role of platelet to lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Yongzhao Zhao; Guangyan Si; Fengshang Zhu; Jialiang Hui; Shangli Cai; Chenshen Huang; Sijin Cheng; Abdel Hamid Fathy; Yi Xiang; Jing Li
Journal:  Oncotarget       Date:  2017-04-04

10.  Preoperative Ratio of Neutrophils to Lymphocytes Predicts Postresection Survival in Selected Patients With Early or Intermediate Stage Hepatocellular Carcinoma.

Authors:  Shi-Dong Lu; Yan-Yan Wang; Ning-Fu Peng; Yu-Chong Peng; Jian-Hong Zhong; Hong-Gui Qin; Bang-De Xiang; Xue-Mei You; Liang Ma; Le-Qun Li
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.